To screen clinical and genetic risk factors and examine their combined effect on docetaxel, epirubicin and cyclophosphamide (TEC) regimen-induced liver injury (TEC-ILI). We enrolled 396 breast cancer patients, and TEC-ILI-associated factors were screened by logistic regression analyses. rs4880 and rs2231142 polymorphisms correlated with an increased risk of TEC-ILI.
View Article and Find Full Text PDF